<div id="readability-page-1"><div><div>Biopharmaceutical drug delivery company Halozyme Therapeutics reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 22.1% year on year to $354.3 million. The company’s full-year revenue guidance of $1.34 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $1.72 per share was 5.5% above analysts’ consensus estimates. Halozyme Therapeutics (HALO) Q3 CY2025 Highlights:<ul><li>Revenue: $354.3 million vs analyst estimates of $343.8 million (22.1% year-on-year growth, 3.1% beat)</li><li>Adjusted EPS: $1.72 vs analyst estimates of $1.63 (5.5% beat)</li><li>Adjusted EBITDA: $238.3 million vs analyst estimates of $233.7 million (67.3% margin, 2% beat)</li><li>Adjusted EPS guidance for the full year is $6.30 at the midpoint, beating analyst estimates by 22.5% </li><li>EBITDA guidance for the full year is $910 million at the midpoint, above analyst estimates of $699.2 million</li><li>Operating Margin: 61.5%, up from 56.3% in the same quarter last year</li><li>Free Cash Flow Margin: 49.6%, up from 39.3% in the same quarter last year</li><li>Market Capitalization: $7.91 billion</li></ul>Company OverviewKnown for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration.Revenue GrowthExamining a company’s long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Halozyme Therapeutics grew its sales at an incredible 44.2% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Halozyme Therapeutics’s annualized revenue growth of 26.2% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. <figure></figure>This quarter, Halozyme Therapeutics reported robust year-on-year revenue growth of 22.1%, and its $354.3 million of revenue topped Wall Street estimates by 3.1%. Looking ahead, sell-side analysts expect revenue to grow 28.1% over the next 12 months, an improvement versus the last two years. This projection is eye-popping and implies its newer products and services will catalyze better top-line performance. While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our free report one of our favorites growth stories.Adjusted Operating MarginAdjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals. Halozyme Therapeutics has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 60.9%. Analyzing the trend in its profitability, Halozyme Therapeutics’s adjusted operating margin decreased by 10.5 percentage points over the last five years, but it rose by 5.9 percentage points on a two-year basis. We like Halozyme Therapeutics and hope it can right the ship. This quarter, Halozyme Therapeutics generated an adjusted operating margin profit margin of 61.5%, down 5.4 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Earnings Per ShareWe track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable. Halozyme Therapeutics’s EPS grew at an astounding 104% compounded annual growth rate over the last five years, higher than its 44.2% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its adjusted operating margin didn’t improve. We can take a deeper look into Halozyme Therapeutics’s earnings to better understand the drivers of its performance. A five-year view shows that Halozyme Therapeutics has repurchased its stock, shrinking its share count by 13.9%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings. <figure></figure>In Q3, Halozyme Therapeutics reported adjusted EPS of $1.72, up from $1.27 in the same quarter last year. This print beat analysts’ estimates by 5.5%. Over the next 12 months, Wall Street expects Halozyme Therapeutics’s full-year EPS of $5.63 to grow 35.1%. Key Takeaways from Halozyme Therapeutics’s Q3 ResultsWe were impressed by Halozyme Therapeutics’s optimistic full-year EBITDA guidance, which blew past analysts’ expectations. We were also excited its full-year EPS guidance outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this was a good print with some key areas of upside. Investors were likely hoping for more, and shares traded down 1.6% to $66.25 immediately following the results. Is Halozyme Therapeutics an attractive investment opportunity at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free for active Edge members.</div></div></div>

HALO

Halozyme Therapeutics (NASDAQ:HALO) reported Q3 CY2025 results with revenue of $354.3 million, exceeding analyst expectations by 3.1% and showing a 22.1% year-on-year growth. The company’s adjusted EPS of $1.72 also beat estimates by 5.5%. Full-year revenue guidance is set at $1.34 billion, 1.5% above forecasts. Despite strong results, shares fell 1.6% to $66.25 post-announcement. The company has demonstrated significant long-term growth, with a 44.2% compounded annual growth rate over five years, although recent growth has slowed to 26.2% annually over the last two years.

Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025